Clinical Trial Update: Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of paclitaxel plus bevacizumab for metastatic or unresectable angiosarcoma has been terminated, with results posted in March 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Stanford University | Conditions: Angiosarcomas, Soft Tissue Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2018-03-26